Cloud technology is enabling more clinical trial sponsors to meet health authorities' increasing demands for trial master file accessibility and completeness.
Cloud technology is enabling more clinical trial sponsors to meet health authorities’ increasing demands for trial master file (TMF) accessibility and completeness, according to a new survey from Veeva Systems.
More trial sponsors now provide auditors with remote access to their electronic TMF. Over 32% of TMF owners surveyed in the “Veeva 2014 Paperless TMF Survey: An Industry Benchmark” said they will grant auditors remote access to their e-TMF by early 2015, versus the 16% who provide them access today. An additional 12% of respondents indicated they will give remote access to their eTMF as soon as they have the technology to support it.
These findings come just months after the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) issued new guidelines on TMF accessibility. Repeated inspection delays due to inaccessible and incomplete sponsor TMFs prompted the MHRA to update its definition of a critical GCP inspection finding to include TMF accessibility and availability, noted the authors of the survey. In 2013, 33% of commercial sponsor inspections required extra days due to an incomplete TMF or lack of accessibility, and nearly 30% of inspectors in the U.K. refuse to use paper and require access to an eTMF, according to the Drug Information Association (DIA) 2014 TMF survey.
“The dramatic rise in sponsors planning to provide remote access is not surprising,” said Jennifer Goldsmith, vice president of Veeva Vault. “Mounting regulatory demands around the globe and growing familiarity with web-accessible content have triggered a shift away from paper-based systems to process-driven eTMF solutions. Further, the anytime-anywhere availability of cloud eTMFs, along with their heightened control and visibility, make them a very compelling industry solution.”
Modern cloud technologies provide secure access to the eTMF over the web, enabling sponsors and partners to work together in real time, and collaborators can log in from any device, modify documents, and save them back to the central repository in the cloud for a single source of the truth, she explained.
For 76% of survey respondents with an eTMF application, an integration with their clinical trial management system is seen as critical to achieving a paperless TMF – indicating that full integration across the clinical ecosystem becomes crucially important as organizations progress along the technology maturity curve. Similarly, 61% of these respondents also cite integration with an electronic data capture system as an essential component. These types of integrations allow workflows to extend beyond a single technology and create greater visibility into the status and completeness of the TMF.
Read the full release here.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.